GSK files for U.S. approval of new diabetes drug

Status
Not open for further replies.

Northerner

Admin (Retired)
Relationship to Diabetes
Type 1
GlaxoSmithKline said on Monday it had filed for U.S. approval of its new once-weekly diabetes drug albiglutide and would make a similar submission shortly in Europe as it vies for a share of a crowded market.

Albiglutide belongs to the same class of injectable GLP-1 medicines as Victoza, from Novo Nordisk, and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca's Amylin unit.

http://uk.reuters.com/article/2013/01/14/us-glaxosmithkline-diabetes-idUKBRE90D0HA20130114
 
Status
Not open for further replies.
Back
Top